GlassScriptPhysician profile
Delaney Dean French
NPI 1861405417
$10,537.51
in general payments reported to CMS, 2019-2025
44 companies · $716 in 2025
The $716 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,585 · 2020: $1,740 · 2021: $1,963 · 2022: $1,455 · 2023: $1,298 · 2024: $780 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,793.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,702.98 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,042.82 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $837.35 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $795.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $700.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Supernus Pharmaceuticals, INC. | $684.11 | 2019-2020 | |
| Amarin Pharma, INC. | $665.63 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $582.79 | 2019-2023 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $509.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $437.05 | 2019-2023 | Verquvo |
| Mylan Specialty L.P. | $335.13 | 2020-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $229.10 | 2019-2023 | |
| Pfizer INC. | $204.74 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $203.69 | 2021-2025 | |
| Astellas Pharma US INC | $172.79 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delaney French listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.